Cargando…

FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements

Objectives: Positron emission tomography (PET)/CT with 18F-FDG has proven to be effective in detecting and assessing various types of cancers. However, due to cancer and/or its therapy, intravenous (IV) FDG injection may be problematic resulting in dose extravasations. In the most frequently used fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Osman, Medhat M., Muzaffar, Razi, Altinyay, M. Erkan, Teymouri, Cyrus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356044/
https://www.ncbi.nlm.nih.gov/pubmed/22655246
http://dx.doi.org/10.3389/fonc.2011.00041
_version_ 1782233487188688896
author Osman, Medhat M.
Muzaffar, Razi
Altinyay, M. Erkan
Teymouri, Cyrus
author_facet Osman, Medhat M.
Muzaffar, Razi
Altinyay, M. Erkan
Teymouri, Cyrus
author_sort Osman, Medhat M.
collection PubMed
description Objectives: Positron emission tomography (PET)/CT with 18F-FDG has proven to be effective in detecting and assessing various types of cancers. However, due to cancer and/or its therapy, intravenous (IV) FDG injection may be problematic resulting in dose extravasations. In the most frequently used field of view (FOV), arms-up, and base of skull to upper thigh [limited whole body (LWB)], the injection site may not be routinely imaged. The purpose of this study was to evaluate the frequency of dose extravasations in FDG PET and the potential impact on standard uptake value (SUV) measurements. Methods: True whole body FDG PET/CT scans (including all extremities) of 400 patients were retrospectively reviewed. A log recorded cases of IV dose extravasations. When possible, SUVs were measured in two frequently used reference locations: mediastinum and liver. The SUVs were obtained in the same patients who had studies with and without FDG extravasations within an average of 3 months without interval therapy. Results: Of the 400 scans, 42 (10.5%) had extravasations on the maximum intensity projections images. In scans with or without dose infiltration, FDG injection site was at or distal to the antecubital fossa in 97% of studies. Of those 42 cases, dose infiltration was within the LWB FOV in 29/42 (69%) and outside in the remaining 13/42 (31%). Of those 42 patients, 5 had repeat PET studies with no interval therapy. For those 5 patients, liver maximum SUV was 11.7% less in patients with infiltration than those without (2.22 ± 0.54 vs. 2.48 ± 0.6). Mediastinum SUVmax was 9.3% less in patients with infiltration than those without (1.72 ± 0.54 vs. 1.88 ± 0.49). Conclusion: We conclude dose extravasations were commonly encountered (10.5%) in PET/CT. However, it is underreported by at least 31% due to omitting injection site from the FOV. When present, extravasations may lead to underestimation of SUVmax. Therefore, it should not only be avoided but also reported in order to avoid false interpretations of the exam.
format Online
Article
Text
id pubmed-3356044
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33560442012-05-31 FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements Osman, Medhat M. Muzaffar, Razi Altinyay, M. Erkan Teymouri, Cyrus Front Oncol Oncology Objectives: Positron emission tomography (PET)/CT with 18F-FDG has proven to be effective in detecting and assessing various types of cancers. However, due to cancer and/or its therapy, intravenous (IV) FDG injection may be problematic resulting in dose extravasations. In the most frequently used field of view (FOV), arms-up, and base of skull to upper thigh [limited whole body (LWB)], the injection site may not be routinely imaged. The purpose of this study was to evaluate the frequency of dose extravasations in FDG PET and the potential impact on standard uptake value (SUV) measurements. Methods: True whole body FDG PET/CT scans (including all extremities) of 400 patients were retrospectively reviewed. A log recorded cases of IV dose extravasations. When possible, SUVs were measured in two frequently used reference locations: mediastinum and liver. The SUVs were obtained in the same patients who had studies with and without FDG extravasations within an average of 3 months without interval therapy. Results: Of the 400 scans, 42 (10.5%) had extravasations on the maximum intensity projections images. In scans with or without dose infiltration, FDG injection site was at or distal to the antecubital fossa in 97% of studies. Of those 42 cases, dose infiltration was within the LWB FOV in 29/42 (69%) and outside in the remaining 13/42 (31%). Of those 42 patients, 5 had repeat PET studies with no interval therapy. For those 5 patients, liver maximum SUV was 11.7% less in patients with infiltration than those without (2.22 ± 0.54 vs. 2.48 ± 0.6). Mediastinum SUVmax was 9.3% less in patients with infiltration than those without (1.72 ± 0.54 vs. 1.88 ± 0.49). Conclusion: We conclude dose extravasations were commonly encountered (10.5%) in PET/CT. However, it is underreported by at least 31% due to omitting injection site from the FOV. When present, extravasations may lead to underestimation of SUVmax. Therefore, it should not only be avoided but also reported in order to avoid false interpretations of the exam. Frontiers Research Foundation 2011-11-16 /pmc/articles/PMC3356044/ /pubmed/22655246 http://dx.doi.org/10.3389/fonc.2011.00041 Text en Copyright © 2011 Osman, Muzaffar, Altinyay and Teymouri. http://www.frontiersin.org/licenseagreement This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.
spellingShingle Oncology
Osman, Medhat M.
Muzaffar, Razi
Altinyay, M. Erkan
Teymouri, Cyrus
FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
title FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
title_full FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
title_fullStr FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
title_full_unstemmed FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
title_short FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements
title_sort fdg dose extravasations in pet/ct: frequency and impact on suv measurements
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356044/
https://www.ncbi.nlm.nih.gov/pubmed/22655246
http://dx.doi.org/10.3389/fonc.2011.00041
work_keys_str_mv AT osmanmedhatm fdgdoseextravasationsinpetctfrequencyandimpactonsuvmeasurements
AT muzaffarrazi fdgdoseextravasationsinpetctfrequencyandimpactonsuvmeasurements
AT altinyaymerkan fdgdoseextravasationsinpetctfrequencyandimpactonsuvmeasurements
AT teymouricyrus fdgdoseextravasationsinpetctfrequencyandimpactonsuvmeasurements